Open access
307
Views
6
CrossRef citations to date
0
Altmetric
Review
Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy
Shimon Lecht1 Department of Pharmacology and Experimental TherapeuticsJerusalem, Israel;3 This manuscript is a part of PhD thesis to be submitted to The Hebrew University of Jerusalem by SL;4 These authors contributed equally in preparation of this manuscript
, Simon Haroutiunian2 Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of JerusalemJerusalem, Israel;4 These authors contributed equally in preparation of this manuscript
, Amnon Hoffman2 Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of JerusalemJerusalem, Israel
& Philip Lazarovici1 Department of Pharmacology and Experimental TherapeuticsJerusalem, IsraelCorrespondence[email protected]
Pages 467-474
|
Published online: 28 Dec 2022
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.